LAG-3+ tumor-infiltrating lymphocytes ameliorates overall survival in triple-negative breast cancer patients
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
LAG-3+ tumor-infiltrating lymphocytes ameliorates overall survival in triple-negative breast cancer patients
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2023-01-25
DOI
10.3389/fonc.2022.986903
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- TIM3 expression on TILs is associated with poor response to neoadjuvant chemotherapy in patients with locally advanced triple-negative breast cancer
- (2021) Neslihan Cabioglu et al. BMC CANCER
- Prognostic and Clinicopathologic Associations of LAG-3 Expression in Triple-negative Breast Cancer
- (2021) Elisabeth S. Stovgaard et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
- (2021) Jinhua Liu et al. Frontiers in Pharmacology
- Clinical Significance of Expression of Immunoadjuvant Molecules (LAG-3, TIM-3, OX-40) in Neoadjuvant Chemotherapy for Breast Cancer
- (2021) YUKA ASANO et al. ANTICANCER RESEARCH
- Prognostic Implications of Immune Infiltrates in the Breast Cancer Microenvironment: The Role of Expressions of CTLA-4, PD-1, and LAG-3
- (2021) Sidar Bagbudar et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- Prognostic value of immune checkpoint molecules in breast cancer
- (2020) Jun Fang et al. BIOSCIENCE REPORTS
- Importance of CD45RO+ tumor-infiltrating lymphocytes in post-operative survival of breast cancer patients
- (2019) Simin Ahmadvand et al. CELLULAR ONCOLOGY
- Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes
- (2019) Deborah B Doroshow et al. CLINICAL CANCER RESEARCH
- Lymphocyte-Activation Gene-3 Expression and Prognostic Value in Neoadjuvant-Treated Triple-Negative Breast Cancer
- (2018) Yunxuan Wang et al. Journal of Breast Cancer
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- LAG-3 Protein Expression in Non–Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes
- (2017) Yayi He et al. Journal of Thoracic Oncology
- Elements of cancer immunity and the cancer–immune set point
- (2017) Daniel S. Chen et al. NATURE
- Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
- (2016) Ana C. Anderson et al. IMMUNITY
- LAG-3 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma
- (2016) Wei-Wei Deng et al. OncoImmunology
- Cytotoxic T lymphocyte antigen 4 expression in human breast cancer: implications for prognosis
- (2015) Haiming Yu et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer
- (2015) N. A. Giraldo et al. CLINICAL CANCER RESEARCH
- The effect of immune microenvironment on the progression and prognosis of colorectal cancer
- (2014) Jinxiang Chen et al. MEDICAL ONCOLOGY
- Programmed death ligand-1 expression in non-small cell lung cancer
- (2013) Vamsidhar Velcheti et al. LABORATORY INVESTIGATION
- Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses
- (2010) Andreas Stang EUROPEAN JOURNAL OF EPIDEMIOLOGY
- Triple-negative breast cancer--current status and future directions
- (2009) O. Gluz et al. ANNALS OF ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now